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Summary 
Annual MDA with DP over two years reduced malaria infection and clinical disease incidence; the 
decrease in clinical malaria was not sustained in eastern Gambia. Multiple MDA rounds over large 
areas may result in larger and sustained reduction in transmission. 
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Abstract 
Background 
Mass drug administration (MDA) may further reduce malaria transmission in low transmission areas. 
The impact of MDA on dynamics of malaria transmission was determined in a prospective cohort 
study.  
Methods 
Annual rounds of MDA with dihydroartemisinin-piperaquine (DP) were implemented over two years 
(2014 and 2015) in six village pairs before the malaria transmission season.  Monthly blood samples 
were collected from all residents between July and December for microscopy and nested PCR. The 
incidence and prevalence of infection and clinical disease, and the risk of malaria re-infection post-
MDA were determined.  
Results 
Coverage of three DP doses was 68.2% (2014) and 65.6% (2015), compliance was greater than 80%.  
Incidence of infection was significantly lower in 2014 (IR=0.2 PPY) than in 2013 (IR=1.1 PPY) (P<0.01); 
monthly infection prevalence declined in the first three months post-MDA. Clinical malaria incidence 
was significantly lower in 2014 (IR=0.1 PPY) and 2015 (IR=0.2 PPY) than in 2013 (IR=0.4 PPY) (P<0.01) 
but remained higher in eastern Gambia. Individuals infected before MDA had a 2-fold higher odds of 
re-infection post-MDA (AOR=2.5, 95% CI: 1.5-4.3, P<0.01). 
Conclusions 
MDA reduced malaria infection and clinical disease during the first months of each transmission 
season. The reduction was maintained in low transmission areas, but not in eastern Gambia. One 
MDA round could be followed by focal MDA targeting individuals found infected during the dry 
season. Repeated MDA rounds, some of them during the dry season over a much larger geographical 
area, may result in a more marked and sustained decrease of malaria transmission. 
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Introduction 
Malaria causes approximately 216 million cases and 445,000 deaths annually, most of them in 
Sub-Saharan Africa (SSA). Plasmodium (P) falciparum is the main species [1], with the other species 
representing less than 5% of infections in Western Africa [2, 3]. Malaria has decreased over the last 
decades worldwide, including in The Gambia [4], where its transmission has become heterogeneous, 
with infection prevalence of 10-40% in the east and <5% in the west [5-8]. 
The World Health Organization (WHO) recommends mass drug administration (MDA), which is a 
full course of an antimalarial treatment to the whole population [9, 10], for areas approaching 
malaria elimination [9, 11]. Successful campaigns, besides treatment efficacy, depend on high 
coverage and good compliance [12]. MDA with an artemisinin-based combination treatment (ACT) 
reduces transmission by clearing asexual infections and early stage gametocytes in asymptomatic 
infected individuals [11]. Dihydroartemisinin-piperaquine (DP) is used for MDA because of its simple 
dosing schedule, its long post-treatment prophylaxis period [13-15], and good safety profile [16]. 
Recent reviews on DP safety [17] did not confirm earlier reports of increases and prolongation of the 
QTc interval within 48 hours [14, 18].  
The objectives of this study were to describe the malaria transmission dynamics following one 
yearly MDA round with DP for two consecutive years, and to determine the risk of malaria re-
infection after each MDA round.  
Methods 
Study sites and follow up 
Malaria transmission in The Gambia is seasonal (July-December), with little transmission during 
the dry season (January-June). In 2013, a cohort including all residents was set up in six pairs of 
villages in five regions; West Coast Region (WCR), North Bank Region (NBR), Lower River Region 
(LRR), Central River Region (CRR), Upper River Region divided in the north (URR-N) and south (URR-
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S). Villages in each pair were 1-3km apart and close to the Senegalese border (Figure 2). Residents 
were predominantly farmers. 
Residents who provided written informed consent were enrolled in May 2013 and included in 
monthly surveys during three transmission seasons (2013-2015; June-December). An additional 
survey was done during the dry season in both 2014 and 2015. Information on malaria symptoms, 
treatment, and risk factors was collected as well as a finger-prick blood sample for haemoglobin 
measurement, thick blood smears and dried blood spots (Whatman 3 Corporation, Florham Park, NJ, 
USA). Clinical malaria cases were identified by passive detection at health facilities. Participants with 
history of fever in the previous 24 hours and/or axillary temperature greater than 37.5oC had a rapid 
diagnostic test (Paracheck Pf, Orchid Biomedical System, India) and positives were treated with 
artemether-lumefantrine. Mean monthly rainfall data were collected from regional meteorology 
stations.  
Mass drug administration with DP   
In 2014 and 2015, MDA with DP was implemented over 6 to 14 days in June and May, 
respectively, across all study villages. DP was administered to participants aged 6 months to 75 years 
old, body weight ≥5kg, and no known history of cardiac or renal disease. Women aged 11-45 years 
were offered a urine human chorionic gonadotropin pregnancy test; positive women were excluded 
and referred to antenatal care clinics for intermittent preventive treatment (IPTp). Residents who 
had travelled and returned after the MDA did not receive DP (Figure 1).   
Treatment administration 
DP (Eurartesim®, Sigma-Tau, Industrie Farmaceutiche Riunite, Italy) administration according to 
weight-based dosing guidelines was directly observed by five field research teams working with 
government nurses and village health workers.  
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Safety profile 
Adverse events (AEs) were monitored passively for 28 days. Relatedness of AEs to the 
intervention was based on known DP side-effects and timing after treatment. AEs were graded by 
severity as mild, moderate or severe.  
Molecular Diagnostics and Parasitology 
P. falciparum was detected by nested PCR from the blood spot samples collected in 2014 monthly 
surveys. Briefly, DNA was extracted using an automated QIAxtractor robot (Qiagen) and 4µl used in a 
nested PCR [19]. All PCR products were run with the QIAxcel capillary electrophoresis system 
(Qiagen) using the screening cartridge and 15-1000 bp-alignment markers. Results were exported 
and double scored using both the QIAxcel binary scoring function and manually by visualisation of 
the gel images; discrepancies were scored by a third reader.  
Thick smears from all the positive nested PCR samples and clinical malaria cases (n=1480) were 
read by two independent microscopists and discrepancies settled by a third reader. Parasite density 
was estimated by number of parasites per 200 WBC, assuming 8,000 WBC/μL. Blood smears were 
considered negative after reading 100 high power fields.  
Consent 
Verbal approval was obtained at village sensitization meetings in May-April 2013-2015 and two 
weeks prior to the MDA. Information sheets were given to all study participants. Written individual 
consent was obtained from literate adults; parents or guardians consented for children <12 years 
and children 12 <18 years provided assent. The study was approved by the Gambia 
Government/Medical Research Council Ethics Committee (SCC 1318). Approval to import DP was 
obtained from the Gambian Medicine Control Agency. 
Data management  
 Data were captured using case report forms and verified for internal consistency by the field 
coordinators. Data were double entered using the SQL program version 36, verified and cleaned.  
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Study outcomes 
The primary outcome was malaria (P. falciparum) infection determined by nested PCR; secondary 
outcomes included DP coverage and compliance, incidence of clinical malaria, prevalence of 
gametocytaemia, asymptomatic and sub-patent infections and AEs. Asymptomatic malaria was an 
infection by nested PCR in an afebrile individual with no history of fever in the previous 24 hours 
[20]. Clinical malaria was defined as positive microscopy or RDT with history of fever or temperature 
>37.50C [15]. Sub-patent infections were infections positive by nested PCR and negative by 
microscopy.  
Statistical analysis 
The incidence rates of infection and clinical malaria were the number of infections or clinical 
cases divided by the total person-time at risk (per-person per year, PPY). Prevalence of 
asymptomatic infection was the number of infections divided by the number of individuals with no 
history fever. DP coverage was the number of treated individuals who received three DP doses 
divided by the village population. Compliance was the proportion of eligible individuals who had full 
treatment. Gametocyte prevalence was the number of individuals with gametocytes divided by total 
number of infected individuals by microscopy.  
Risk ratio of infections and incidence rate ratio (IRR) of clinical malaria, before and after MDA, were 
estimated by comparing prevalence and incidence in April 2014 with July-December 2014; and the 
2013 transmission season with the 2014 and 2015 transmission seasons. DP efficacy was determined 
in 2014 for treated individuals sampled between days 14 to 28 and around day 42. For participants 
infected in the dry season (April), logistic regression models were fitted to determine the odds of 
infections at 4 weeks and around day 42 post-MDA. Protective efficacy for clinical malaria was 
determined for 2014 and 2015 post-MDA using a mixed effects logistic regression model accounting 
for clustering at regional level. Multivariable models were adjusted for age, gender, LLIN use, 
sleeping outdoors and travel history. Analyses were performed using Stata version 13.0 [21]. 
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Results  
A total of 4,312 and 4,189 individuals were followed in 2014 and 2015, respectively. The median 
age was 13 years (IQR: 5, 28). LLIN use the previous night was low in April (2014: 43.3%, 1374/3171; 
2015: 51.8%, 1545/2982), but increased substantially during and after the rainy season; overall use 
was 87.8% (3072/3501) in 2014 and 77.9% (2940/3771) in 2015. Few residents travelled; 4.8% 
(946/22,795) in 2014 and 3.9% (149/3738) in 2015, with median of 22 (IQR: 12, 31) days absence 
(Table 1).  
 Screening for MDA was done for 86.4% (3725/4312) and 80.54% (3374/4189) of potential 
participants in 2014 and 2015, respectively; 5% of them were non-eligible mainly because of 
pregnancy. In 2014, 763 individuals did not participate because they were absent (66.1%, 504/763) 
or refused (22.7%, 173/763). In 2015, 55.6% (470/845) were away or (26.1%, 259/845) refused. 
Compliance to three DP doses was 83.1% (2942/3540) in 2014 and 85.93% (2748/3198) in 2015 
(Figure 1). Coverage of the three doses was 68.2% (2942/4312) in 2014 and 65.6% (2748/4189) in 
2015.  
Monthly infection prevalence was significantly lower during the whole 2014 transmission season, 
after MDA, than in 2013 (2014: 5.9%, 1307/22036, 2013: 8.7%, 1796/20552, RR=0.7, P<0.01). 
Malaria prevalence was significantly lower in the 3 months following MDA, i.e. July (5.9%,188/3150, 
RR=0.8 P=0.02) August (4.7%, 160/3411, RR=0.6 P<0.0)1 and September (1.9%, 60/3252, RR=0.3 
P<0.01) than in April 2014 (7.5%,213/2827) (Table 2).   
In 2014 and all regions, incidence of infections was significantly lower than in 2013 
(Supplementary Table 1 and Figure 2). Malaria prevalence remained significantly higher in URR-S 
(355/5208, 6.8%) and URR-N (244/2342, 10.4%) than in WCR (P<0.01) (Supplementary Table 2). In 
2014, the largest reduction in malaria prevalence was in eastern Gambia; in November, at peak 
transmission, asymptomatic malaria prevalence was lower in 2014 than in 2013; it decreased by 50% 
or more in URR-S (65.2% reduction, 2013=13.6%, 92/679 versus 2014=4.7%, 31/658, Risk Ratio=0.05 
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P<0.01), URR-N (57.9%, 2013=36.4%, 122/335 versus 2014=15.3%, 53/346, Risk Ratio=0.2, P<0.01) 
and LRR, (49.7% reduction, 2013=8.9%, 39/436 versus 2014=4.5%, 15/333, Risk Ratio=0.5, P=0.001) .  
 More than half of all infections were sub-patent in 2014 [April: 55.1% (92/167); July: 50% 
(65/129); August: 50.4% (65/129); September 68.3%, (41/60); October 58.1% (118/203); November 
56.3% (126/224); December 68% (41/60)]. Overall gametocyte carriage during the 2014 transmission 
season was 8.3% (46/552); and lower in August (2/70, 2.9%) than in April (8/87, 9.2%) 
(Supplementary Table 3). Median P. falciparum densities were significantly lower in the 2014 
transmission season compared to 2013 in all regions but URR-N (Figure 4). One P. malariae infection 
was detected in 2014, before MDA, and seven P. ovale infections in 2013. 
 In 2014, malaria prevalence between 14-28 days and 42 days post-MDA was 5.5% (131/2432) and 
4.2% (147/3534), respectively, with half infections (49.6%, 65/131) sub-patent. MDA decreased the 
risk of being infected but the difference between treated and untreated individuals was statistically 
significant only for those who had received the 3-day treatment, both in July (AOR: 0.6; 95%CI: 0.4-
1.0) (P=0.04) and August (AOR: 0.5; 95% CI: 0.3-0.9, P=0.02) (Table 3). 
The odds of clinical malaria in July 2014 were significantly lower among subjects who took three DP 
doses (AOR=0.3, 95% CI: 0.1-0.9, P=0.02) compared to untreated individuals. At 3-4 weeks post-MDA 
2014, nineteen (8.92%) individuals among the 213 infected in April were still infected, 10 had 
received the full 3-day treatment, more than half (52.6%, 10/19) being patent infections.  
Efficacy of MDA in clearing and preventing infections was assessed in 2,276 individuals who 
received full treatment and with known infection status in both July and August 2014. Among the 
113 individuals infected in July 2014, 89.4% (101/113) had cleared the infection by August; only 82 
(3.8%) among the 2,163 individuals not infected in July became infected in August.  
Individuals infected in the dry season (2014) had a 2-fold higher odds of being infected in July 
(AOR=2.5, 95% CI: 1.5-4.3, P<0.01), August (AOR=2.8, 95% CI: 1.6-5.1, P=0.001) and throughout the 
transmission season (AOR=2.5, 95% CI: 1.7-3.6, P<0.01) (Supplementary Table 4). 
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The odds of clinical malaria were significantly lower in 2014 (AOR=0.4, 95% CI: 0.3-0.6, P<0.01) 
and 2015: AOR=0.6, 95% CI: 0.5-0.7, P<0.01) in fully treated than in untreated individuals (Table 4). 
Incidence of clinical malaria was significantly lower in all regions after the first and second MDA than 
in 2013. (Supplementary Table 5) Incidence of clinical malaria was similar after the first and second 
MDA round, except in URR-S and URR-N where incidence was significantly higher in 2015 than in 
2014 (Figure 3 and Supplementary Table 5). In URR, rainfalls lasted longer (May-December) in 2015 
than in 2013 and 2014 (Figure 3). 
Dihydroartemesinin-piperaquine safety 
Within the 28 days post-MDA, 302 and 269 AEs were reported in 2014 and 2015, respectively, 
with similar proportions of symptoms in both years. The most common AEs were headache (2014 
=18.9%, 57/302: 2015=18.2%, 49/269), fever (2014=12.6%, 38/302: 2015=11.5%, 31/269), malaise 
(2014=11.9%, 36/302: 2015=12.6%, 34/269), and vomiting (2014=11.3%, 34/302: 2015=10.0%, 
27/269). AEs were either mild or moderate in severity and were all probably related to DP except for 
fever and chills. (Supplementary Table 6) No serious adverse events were detected.  
Discussion 
We  assessed the impact of an annual round of MDA with DP, an ACT with a long post-treatment 
prophylactic period, on malaria transmission dynamics over two consecutive years and in areas of 
differing transmission intensity in The Gambia. [8].  
Prevalence and incidence of infection in 2014 were significantly lower than in 2013 but remained 
significantly higher in eastern Gambia compared to other regions. Monthly prevalence, after a 
significant decrease in the first 3 months post-MDA, returned to similar pre-MDA levels. Clinical 
malaria decreased in both intervention years but remained significantly higher in eastern Gambia, 
increasing in the second year compared to the first, confirming the higher transmission intensity in 
this region. [8, 22].  One annual MDA round over two consecutive years resulted in a temporal 
decline of malaria infections and clinical disease, with a temporal shift and  decrease in  the peak 
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prevalence and incidence of infection and clinical disease. In The Gambia, MDA with sulfadoxine-
pyrimethamine and a single artesunate dose resulted in a lower incidence of clinical malaria for two 
months following MDA [10]. Two MDA rounds in Zambia showed lower prevalence for at least six 
months in the low transmission sites [11]. In Myanmar, MDA with DP and a single low dose of 
primaquine significantly reduced P. falciparum prevalence three months after MDA in intervention 
villages compared to controls [19]. Therefore, although WHO currently recommends MDA where 
transmission is low, such recommendations could be extended to moderate transmission areas given 
the substantial but time-limited decrease in prevalence and incidence we observed. Multiple MDA 
rounds could result in a larger and more sustained reduction [23], particularly if appropriately timed; 
for example a round during the dry season could decrease the human reservoir before transmission 
begins. In addition, DP could be combined with invermectin, that would reduce mosquito survival 
[24]. 
One annual MDA round was unable to maintain the observed malaria decline throughout the 
transmission season. Nevertheless, incidence of clinical malaria in the western and central regions 
remained low across the two intervention years while in eastern Gambia we observed an increase 
during the second year, probably due to environmental factors such as the longer duration of rainfall 
that resulted in higher mosquito density and survival. Therefore, in low transmission areas such as 
western and central Gambia, one appropriately-timed annual MDA round could reduce the clinical 
case burden on the health care system and maintain this effect over time if implemented regularly. 
Cost-benefit comparisons between this approach and clinical case management are needed to 
confirm this potential value. As the intervention was implemented in two villages in each region, 
transmission may have been maintained by population movements [25-27]. Increasing the size of 
the intervention area, extending the duration of campaigns and ensuring individuals who missed 
MDA are prioritised in additional rounds would achieve a larger effect [23]. Since transmission 
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intensity varied substantially by year and there were no control villages, it is not possible to quantify 
the MDA’s additional (to standard control interventions) impact on malaria transmission.  
MDA coverage was relatively high and comparable to previous studies;  85% in The Gambia [28],  
>95% in Tanzania [29], 72%-88% in Zambia [30], and 28%-61% in Myanmar [31]. Villages where 
coverage was below 70% had high proportions of people traveling or refusing despite meetings and 
mobilization campaigns, highlighting the main challenges for MDA implementation [32, 33]. 
Compliance was high as doses were directly observed but it may be lower in programmatic 
conditions [34].   
In both intervention years, full DP treatment significantly reduced the risk of clinical malaria 
throughout the transmission season. This is due to the excellent DP efficacy and long post-treatment 
prophylaxis related to the long elimination half-life of piperaquine (20 days in children and 22 days in 
adults) [9, 12-14, 16, 35]. Incomplete treatment was not protective, probably due to the shortened 
post-treatment prophylaxis [36]. It is not possible to determine whether infections observed at days 
28-42 were residual or new infections as no genotyping was done. About half of them were 
detectable only by molecular methods. Low-density infection is common following ACT treatment, 
31.8% of children treated with an ACT had residual parasitaemia detected by quantitative (q) PCR at 
day 3 post-treatment [37] while 25% of patients treated with an ACT had parasitaemia at day 14 
detected by qRT-PCR [38].  Therefore, a substantial proportion of infections detected after MDA may 
be residual and not new infections.    
Individuals infected in April 2014, had a significantly higher risk of infection during the 
transmission season. Such risk is probably due to higher exposure, e.g. close proximity to breeding 
sites or an environment favoring exposure to the vector, and not to residual parasitaemia or 
gametocytaemia as the latter would decrease after two months [39, 40]. This suggests that risk of 
infection and clinical disease is extremely focal as already shown in The Gambia [8], Senegal [41], 
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and Kenya [42]. Besides treating the whole population, households with infected individuals at the 
beginning of the transmission season could be targetted with focal MDA [30].  
The RDT for the diagnosis of clinical malaria, the Paracheck Pf, did not perform well at low 
parasite densities (200/µl) during the last WHO evaluation round [50]. This RDT was used only to 
diagnose clinical malaria cases which have higher parasite densities. Therefore, considering that 
Paracheck Pf had a high panel detection score at parasite densities of 2,000/µl, it is unlikely clinical 
malaria cases would have gone undiagnosed.  
Conclusions 
Annual MDA with DP reduced prevalence and incidence of infection and clinical disease in the 
first months of each transmission season. In western and central Gambia, where transmission is low, 
clinical malaria incidence was reduced over two years, despite an apparent higher transmission 
during the second year. One MDA round could be followed by MDA targeting households with 
individuals identified as infected during the dry season. Repeated MDA rounds, some of them during 
the dry season and over a much larger geographical area, may result in a more marked and 
sustained decrease of malaria transmission.  
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Figure legends 
Figure 1: Study flow diagram  
Figure 2: Study sites and monthly malaria prevalence and incidence of infection by region before 
(2013) and after (2014) one annual MDA round  
Figure legend  
 
Prevalence of asymptomatic infection 
 
Incidence rate of infection 
Figure 3: Monthly incidence of clinical malaria by region before (2013) and after (2014) one annual 
MDA round 
Figure legend 
 
Incidence rate of clinical malaria  
 
Rainfall (mm) 
Figure 4: Monthly prevalence and density of P. falciparum infections before and after one MDA 
round 
Figure legend 
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Table 1: Study subjects characteristics 
Characteristic 2014 n (%) 2015 n (%) 
Gender    
Male 1966 (46.1) 1932 (46.1) 
Female 2296 (53.9) 2256 (53.9) 
Age category    
≤ 5 years 1091 (25.6) 1054 (25.2) 
6-15 years 1336 (31.4) 1433 (34.2) 
≥ 16 years 1830 (42.9) 1702 (40.6) 
LLIN use previous night    
April 1374/3171 (43.3) 1545/2982 (51.8) 
June*  - 2201/3106 (70.9) 
July 2222/3318 (66.9) 2011/2984 (67.4) 
August 3184/3542 (89.9) 2599.3024 (85.9) 
September 3122/3281 (95.2) 2769/2938 (94.3) 
October 3146/3310 (95.1) 2808/2950 (95.2) 
November 3003/3163 (94.9) 2532/2800 (90.4) 
December 2879/3191 (90.2) 2112/2806 (75.3) 
Travelled in the last month   
April 251/3161 (7.9) 218/2956 (7.4) 
May  228/3079 (7.4) 
July 277/3287 (8.4) 40/2966 (1.4) 
August 86/3500 (2.5) 31/3008 (1.0) 
September 126/3255 (3.9) 37/2921(1.3) 
October 95/3279 (2.9) 69/2925 (2.4) 
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November  59/3133 (1.9) 26/27770 (1.3) 
December 52/3170 (1.6) 39/2796 (1.4) 
house structure (N=2233)  2111 (75.3) 
traditional house (1) 1182 (52.9)  
modern house (0) 1051 (47.1)  
*No survey was conducted in June 2014 before the MDA campaign 
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Table 2: Malaria prevalence by month and year; risk ratio (RR) of infection by month 
Month 2013 
Prevalence  
(n/N) 
2014 
Prevalence 
(n/N) 
RR 2013 vs 2014 
by month  
(95% CI)  
P-value RR April 2014 vs 
other months 
2014 (95% CI) 
 P-
value 
April  NA 7.5 (213/2827)   1  
       
June 5.3 
(75/1409) 
NA   NA  
July 5.3 
(180/3411) 
5.9 
(188/3150) 
1.1  
(0.9-1.4) 
0.2 0.8 
(0.7- 0.9) 
0.02 
August 6.2  
(195/3133) 
4.7  
(160/3411) 
0.8  
(0.6-0.9) 
 0.01 0.6  
(0.5-0.8) 
 <0.01 
September 5.1  
(146/2867) 
1.8  
(60/3252) 
0.4  
(0.3- 0.5) 
 <0.01 0.24  
(0.2 -0.3) 
 <0.01 
October 11.2 
(347/3113) 
6.7  
(210/3156) 
0.6 
(0.5-0.7) 
 <0.01 0.9  
(0.7 -1.1) 
 0.2 
November 14.4 
(503/3492) 
7.6  
(247/3240) 
0.6  
(0.5-0.7) 
 <0.01 1.0  
(0.9 -1.2) 
0.9 
December 11.2  
(350/3127) 
7.6 
(229/3000) 
0.7  
(0.6-0.8) 
 <0.01 1.0  
(0.8-1.2) 
0.9 
Total 8.7  
(1796/20552) 
5.9 
(1307/22036) 
0.7  
(0.65-0.8) 
<0.01   
     NA : not available 
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Table 3: Risk factors of malaria infection 14-28 days (July 2014) and 42 days (August 2014) after 
MDA  
 Day 14-28  Day 42  
 AOR (95%CI) P-value AOR (95%CI) P-value 
MDA DP      
No treatment 1  1  
1-2 doses 0.7 (0.4-1.3)  0.3  0.6 (0.3-1.2)  0.1 
Three doses 0.6 (0.4-1.0)  0.04 0.5 (0.3-0.9)  0.02 
Age group     
≤ 5 years 1  1  
6-17 years 1.2 (0.8-1.9)  0.4 1.2 (0.8-1.8)  0.3 
≥ 18 years 0.9 (0.5-1.4)  0.5 0.9 (0.6-1.4)  0.4 
LLIN use previous 
night  
    
 No 1  1  
 Yes 1.4 (0.9-1.9)  0.08 1.0 (0.6-1.4)  0.8 
Gender      
Male   1  
Female   0.8 (0.6-1.1)  0.2 
Study site     
WCR   1  
NBR   1.2 (0.6-2.3)  0.6 
LRR   1.7 (0.9-3.2)  0.12 
CRR   0.9 (0.4-1.9) 0.8 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy870/5125954 by guest on 17 D
ecem
ber 2018
 23 
 
URR-S    1.0 (0.52-1.74)  0.9 
URR-N   4.9 (2.8-9.0) <0.01 
     OR: Odds Ratio; AOR: Adjusted Odds Ratio 
* Variables with P value < 0.1 in the univariate analysis, (“gender” and “study sites") or were 
confounders (“LLIN use at night” and “age groups”) were included in multivariate analysis. Variables 
with P value >0.1 in univariate analysis “sleeping outside” and “travel history” were excluded in the 
multivariate analysis 
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Table 4: Risk factors of clinical malaria post-MDA by year  
 2014 transmission season 2015 transmission season 
 AOR 
(95% CI) 
P-value AOR 
(95% CI) 
P-value 
MDA DP     
No treatment 1  1   
1-2 doses 0.7 (0.4-1.4)  0.4 0.7 (0.5-1.0) 0.05 
Three doses 0.4 (0.3-0.6)  <0.01 0.59 (0.5-0.7)  <0.01 
Age group     
≤5 years 1  1  
6-17 years 0.8 (0.5-1.2) 0.3 1.2 (0.9-1.6)  0.1 
≥18 years 0.5 (0.3-0.8)  0.003 0.9 (0.7-1.2)  0.5 
Gender     
Male 1  1  
Female 0.7 (0.5-0.9) 0.02 0.8 (0.6-0.9)  0.02 
LLIN use previous 
night 
    
No 1  1  
Yes 0.5 (0.3-0.7)  <0.01 0.71 (0.5-0.9)  0.02 
Travelled      
No    1  
Yes 0.7 (0.3-1.9)  0.5 1.9 (1.7-2.1)  <0.01 
Month      
April 1  1  
June 0.5 (0.1-0.5) 0.6 0.4 (0.1-1.8) 0.2 
July 0.1 (0.02-0.6) 0.01 0.3 (0.1-1.2) 0.1 
August 0.5 (0.1-1.5) 0.2 1.3 (0.5-3.2) 0.61 
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September 0.8 (0.4-2.4) 0.7 4.5 (2.03-9.9) <0.01 
October 3.2 (1.3-7.9) 0.01 16.8 (7.9-35.7) <0.01 
November 12.7(5.5-9.2) <0.01 26.2 (12.5-54.7) <0.01 
December 1.1(0.5-2.9) 0.8 5.4 (2.5-11.5) <0.01 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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